These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19825933)

  • 1. Clinical trial for Fabry disease faces continuing hurdles.
    Silversides A
    CMAJ; 2009 Nov; 181(11):E251-2. PubMed ID: 19825933
    [No Abstract]   [Full Text] [Related]  

  • 2. [Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].
    Lidove O; Choukroun G; Bekri S; Viot G; Tsimaratos M; Joly D
    Presse Med; 2010 May; 39(5):527-9. PubMed ID: 20194001
    [No Abstract]   [Full Text] [Related]  

  • 3. Agalsidase alfa: specific treatment for Fabry disease.
    Mehta A
    Hosp Med; 2002 Jun; 63(6):347-50. PubMed ID: 12096664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapy.
    Germain DP
    Clin Ther; 2007; 29 Suppl A():S17-8. PubMed ID: 17580237
    [No Abstract]   [Full Text] [Related]  

  • 5. Enzyme replacement in Anderson-Fabry disease.
    Bengtsson BA; Johansson JO; Hollak C; Linthorst G; FeldtRasmussen U
    Lancet; 2003 Jan; 361(9354):352. PubMed ID: 12559898
    [No Abstract]   [Full Text] [Related]  

  • 6. Fabry trial set to answer "political problem".
    Silversides A
    CMAJ; 2009 Sep; 181(6-7):365-6. PubMed ID: 19752140
    [No Abstract]   [Full Text] [Related]  

  • 7. Pediatrics: implementing the promise of early intervention for Fabry disease.
    Raas-Rothschild A
    Clin Ther; 2007; 29 Suppl A():S6. PubMed ID: 17580239
    [No Abstract]   [Full Text] [Related]  

  • 8. Agalsidase: a second look. With hindsight: full data challenge efficacy.
    Prescrire Int; 2003 Oct; 12(67):168-71. PubMed ID: 14619828
    [No Abstract]   [Full Text] [Related]  

  • 9. Agalsidase beta (Fabrazyme) for Fabry disease.
    Med Lett Drugs Ther; 2003 Sep; 45(1165):74-5. PubMed ID: 12968124
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzyme therapy for Fabry patients in jeopardy.
    Silversides A
    CMAJ; 2009 Sep; 181(6-7):E120. PubMed ID: 19752137
    [No Abstract]   [Full Text] [Related]  

  • 11. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
    Wanner C
    Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
    [No Abstract]   [Full Text] [Related]  

  • 12. Agalsidase treatment for Fabry disease: uses and rivalries.
    Schiffmann R
    Genet Med; 2010 Nov; 12(11):684-5. PubMed ID: 20975568
    [No Abstract]   [Full Text] [Related]  

  • 13. [Fabry disease: new clinical research--current therapeutic perspectives].
    Beck M
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):215-7. PubMed ID: 12778772
    [No Abstract]   [Full Text] [Related]  

  • 14. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
    Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
    Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
    [No Abstract]   [Full Text] [Related]  

  • 15. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
    Warnock DG
    J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
    Hollak CE; Linthorst GE
    Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
    [No Abstract]   [Full Text] [Related]  

  • 17. Enzyme replacement in Fabry disease: the essence is in the kidney.
    Schiffmann R
    Ann Intern Med; 2007 Jan; 146(2):142-4. PubMed ID: 17179053
    [No Abstract]   [Full Text] [Related]  

  • 18. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?
    Banikazemi M; Desnick RJ
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):72-3. PubMed ID: 16932395
    [No Abstract]   [Full Text] [Related]  

  • 19. Fabry disease: dose matters.
    Warnock DG; Mauer M
    J Am Soc Nephrol; 2014 Apr; 25(4):653-5. PubMed ID: 24556355
    [No Abstract]   [Full Text] [Related]  

  • 20. First treatment for Fabry's disease.
    FDA Consum; 2003; 37(4):4. PubMed ID: 12971327
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.